DK1758565T3 - Fremgangsm de til identifikation af GLP-1-sekretionsfremkaldende stoffer - Google Patents

Fremgangsm de til identifikation af GLP-1-sekretionsfremkaldende stoffer

Info

Publication number: DK1758565T3
Authority: DK; Denmark
Prior art keywords: procedure; identifying glp; inducers; secretion; secretion inducers
Prior art date: 2005-01-10

Application number

DK06717678T

Other languages

English (en)

Other versions

DK1758565T4 (da

Inventor

James N Leonard

Hussien A Al-Shamma

Robert M Jones

Zhi-Liang Chu

Original Assignee

Arena Pharm Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-01-10

Filing date

2006-01-09

Publication date

2009-09-07

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36570727&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1758565(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2006-01-09 Application filed by Arena Pharm Inc filed Critical Arena Pharm Inc

2009-09-07 Publication of DK1758565T3 publication Critical patent/DK1758565T3/da

2013-02-04 Application granted granted Critical

2013-02-04 Publication of DK1758565T4 publication Critical patent/DK1758565T4/da

Links

102100025101 GATA-type zinc finger protein 1 Human genes 0.000 title 1
101710198884 GATA-type zinc finger protein 1 Proteins 0.000 title 1
DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 title 1
239000000411 inducer Substances 0.000 title 1
230000028327 secretion Effects 0.000 title 1

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
- G01N33/76—Human chorionic gonadotropin including luteinising hormone, follicle stimulating hormone, thyroid stimulating hormone or their receptors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
- G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2857—Seizure disorders; Epilepsy
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2871—Cerebrovascular disorders, e.g. stroke, cerebral infarct, cerebral haemorrhage, transient ischemic event

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Biomedical Technology (AREA)
Epidemiology (AREA)
Hematology (AREA)
Molecular Biology (AREA)
Urology & Nephrology (AREA)
Immunology (AREA)
Endocrinology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Diabetes (AREA)
Food Science & Technology (AREA)
Microbiology (AREA)
Cell Biology (AREA)
Pathology (AREA)
Biotechnology (AREA)
General Physics & Mathematics (AREA)
Biochemistry (AREA)
Analytical Chemistry (AREA)
Physics & Mathematics (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Obesity (AREA)
Ophthalmology & Optometry (AREA)
Reproductive Health (AREA)
Psychology (AREA)

DK06717678.4T 2005-01-10 2006-01-09 Fremgangsmåde til identifikation af GLP-1-sekretionsfremkaldende stoffer. DK1758565T4 (da)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US64308605P	2005-01-10	2005-01-10
US68317205P	2005-05-19	2005-05-19
US72688005P	2005-10-14	2005-10-14
PCT/US2006/000510 WO2006076231A2 (en)	2005-01-10	2006-01-09	Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood glp-1 level

Publications (2)

Publication Number	Publication Date
DK1758565T3 true DK1758565T3 (da)	2009-09-07
DK1758565T4 DK1758565T4 (da)	2013-02-04

Family

ID=36570727

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK06717678.4T DK1758565T4 (da)	2005-01-10	2006-01-09	Fremgangsmåde til identifikation af GLP-1-sekretionsfremkaldende stoffer.
DK07004743T DK1808168T3 (da)	2005-01-10	2006-01-09	Kombinationsterapi til behandling af diabetes og tilstande relateret hertil og til behandling af tilstande, der lindres ved at öge et blod-GLP-1-niveau

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
DK07004743T DK1808168T3 (da)	2005-01-10	2006-01-09	Kombinationsterapi til behandling af diabetes og tilstande relateret hertil og til behandling af tilstande, der lindres ved at öge et blod-GLP-1-niveau

Country Status (35)

Country	Link
US (12)	US20060154866A1 (da)
EP (9)	EP2322151A3 (da)
JP (8)	JP4118323B1 (da)
KR (5)	KR20130140226A (da)
CN (2)	CN103611161A (da)
AR (1)	AR052082A1 (da)
AT (2)	ATE431139T1 (da)
AU (3)	AU2006205164B2 (da)
BR (1)	BRPI0606727A (da)
CA (2)	CA2593427C (da)
CL (1)	CL2010000565A1 (da)
CR (1)	CR9220A (da)
CY (2)	CY1109260T1 (da)
DE (2)	DE602006006765D1 (da)
DK (2)	DK1758565T4 (da)
DO (2)	DOP2006000008A (da)
EA (1)	EA011883B1 (da)
ES (2)	ES2327268T5 (da)
GT (1)	GT200600004A (da)
HN (1)	HN2006000971A (da)
HR (2)	HRP20090403T4 (da)
IL (1)	IL184364A0 (da)
MX (1)	MX2007008376A (da)
NI (1)	NI200700174A (da)
NO (2)	NO331089B1 (da)
NZ (4)	NZ578504A (da)
PA (1)	PA8659301A1 (da)
PE (2)	PE20100398A1 (da)
PL (2)	PL1808168T3 (da)
PT (2)	PT1758565E (da)
RS (2)	RS51174B (da)
SG (2)	SG158876A1 (da)
SI (2)	SI1808168T1 (da)
TW (1)	TW200637534A (da)
WO (1)	WO2006076231A2 (da)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SK286975B6 (sk) *	2001-02-24	2009-08-06	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Xantínové deriváty, spôsob ich výroby, farmaceutický prostriedok s ich obsahom a ich použitie
EP1411968B1 (en)	2001-07-31	2008-09-17	THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES	Glp-1 exendin-4 peptide analogs and uses thereof
US7407955B2 (en)	2002-08-21	2008-08-05	Boehringer Ingelheim Pharma Gmbh & Co., Kg	8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
CN102558155A (zh)	2003-01-14	2012-07-11	阿伦纳药品公司	作为代谢调节剂的芳基和杂芳基衍生物及其所涉及的疾病如糖尿病和高血糖症的预防和治疗
AR045047A1 (es) *	2003-07-11	2005-10-12	Arena Pharm Inc	Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
AU2004257267B2 (en)	2003-07-14	2009-12-03	Arena Pharmaceuticals,Inc	Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
US7501426B2 (en)	2004-02-18	2009-03-10	Boehringer Ingelheim International Gmbh	8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004054054A1 (de)	2004-11-05	2006-05-11	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
EP1838311A1 (en) *	2004-12-24	2007-10-03	Prosidion Limited	G-protein coupled receptor (gpr116) agonists and use thereof for treating obesity and diabetes
MY148521A (en) *	2005-01-10	2013-04-30	Arena Pharm Inc	Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
DOP2006000008A (es) *	2005-01-10	2006-08-31	Arena Pharm Inc	Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
WO2007027225A2 (en)	2005-04-27	2007-03-08	Arena Pharmaceuticals, Inc.	Combination therapy for the treatment of obesity and diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood glp-1 level
BRPI0613505A2 (pt) *	2005-06-30	2011-01-11	Prosidion Ltd	agonistas de gpcr
DE102005035891A1 (de)	2005-07-30	2007-02-08	Boehringer Ingelheim Pharma Gmbh & Co. Kg	8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
US20070179123A1 (en) *	2005-11-08	2007-08-02	Chiang Peter K	Methods and compositions for treating diseases associated with pathogenic proteins
PE20071221A1 (es) *	2006-04-11	2007-12-14	Arena Pharm Inc	Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
CN103536924A (zh)	2006-04-11	2014-01-29	艾尼纳制药公司	使用gpr119受体鉴定可用于增加个体骨质量的化合物的方法
KR101541791B1 (ko)	2006-05-04	2015-08-04	베링거 인겔하임 인터내셔날 게엠베하	다형태
EP1852108A1 (en)	2006-05-04	2007-11-07	Boehringer Ingelheim Pharma GmbH & Co.KG	DPP IV inhibitor formulations
PE20080251A1 (es)	2006-05-04	2008-04-25	Boehringer Ingelheim Int	Usos de inhibidores de dpp iv
US8222261B2 (en) *	2006-07-13	2012-07-17	GlaxoSmithKline, LLC	Chemical compounds
CA2661371A1 (en) *	2006-08-30	2008-03-06	Biovitrum Ab (Publ)	Pyrimidine compounds for treating gpr119 related disorders
CA2672059A1 (en)	2006-12-14	2008-06-26	Merck & Co., Inc.	Acyl bipiperidinyl compounds, compositions containing such compounds and methods of treatment
US7638541B2 (en)	2006-12-28	2009-12-29	Metabolex Inc.	5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
US20100048632A1 (en) *	2007-01-04	2010-02-25	Matthew Colin Thor Fyfe	Piperidine GPCR Agonists
CL2008000017A1 (es) *	2007-01-04	2008-08-01	Prosidion Ltd	Compuestos derivados de heterociclos de nitrogeno y oxigeno, agonistas de gpcr; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la obesidad, diabetes, sindrome metabolico, hiperlipidemia, toleranci
AR064735A1 (es) *	2007-01-04	2009-04-22	Prosidion Ltd	Agonistas de gpcr y composicion farmaceutica en base al compuesto
WO2008141074A1 (en) *	2007-05-10	2008-11-20	Salk Institute For Biological Studies	Identification of compounds that protect against amyloid diseases
WO2009014910A2 (en)	2007-07-19	2009-01-29	Metabolex, Inc.	N-azacyclic substituted pyrrole, pyrazole, imidazole, triazole and tetrazole derivatives as agonists of the rup3 or gpr119 receptor for the treatment of diabetes and metabolic disorders
CL2008002427A1 (es) *	2007-08-16	2009-09-11	Boehringer Ingelheim Int	Composicion farmaceutica que comprende 1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofurano-3-iloxi)bencil]-benceno combinado con 1-[(4-metilquinazolin-2-il)metil]-3-metil-7-(2-butin-1-il)-8-(3-(r)-aminopiperidin-1-il)xantina; y su uso para tratar diabetes mellitus tipo 2.
KR20100055536A (ko) *	2007-09-20	2010-05-26	아이알엠 엘엘씨	Ｇｐｒ１１９ 활성의 조절제로서의 화합물 및 조성물
WO2009117421A2 (en) *	2008-03-17	2009-09-24	Kalypsys, Inc.	Heterocyclic modulators of gpr119 for treatment of disease
US20090270404A1 (en) *	2008-03-31	2009-10-29	Metabolex, Inc.	Oxymethylene aryl compounds and uses thereof
PE20140960A1 (es)	2008-04-03	2014-08-15	Boehringer Ingelheim Int	Formulaciones que comprenden un inhibidor de dpp4
EP2108960A1 (en)	2008-04-07	2009-10-14	Arena Pharmaceuticals, Inc.	Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditons modulated by PYY
EP2297117B1 (en) *	2008-05-19	2012-10-31	Merck Sharp & Dohme Corp.	Bicyclic heterocycle derivatives and use thereof as gpr119 modulators
EP2321308B9 (en) *	2008-07-10	2012-08-08	Prosidion Limited	Piperidine gpcr agonists
UY32030A (es)	2008-08-06	2010-03-26	Boehringer Ingelheim Int	"tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
KR20200118243A (ko)	2008-08-06	2020-10-14	베링거 인겔하임 인터내셔날 게엠베하	메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
BRPI0919288A2 (pt)	2008-09-10	2015-12-15	Boehring Ingelheim Internat Gmbh	teriapia de combinação para tratamento de diabetes e condições relacionadas.
US20200155558A1 (en)	2018-11-20	2020-05-21	Boehringer Ingelheim International Gmbh	Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
KR101054911B1 (ko)	2008-10-17	2011-08-05	동아제약주식회사	디펩티딜펩티다아제-ⅳ의 활성을 저해하는 화합물 및 다른 항당뇨 또는 항비만 약물을 유효성분으로 함유하는 당뇨 또는 비만의 예방 및 치료용 약학적 조성물
CN101723947B (zh) *	2008-10-21	2012-05-30	山东轩竹医药科技有限公司	二肽酶-ⅳ抑制剂化合物
KR20110103968A (ko)	2008-12-23	2011-09-21	베링거 인겔하임 인터내셔날 게엠베하	유기 화합물의 염 형태
WO2010074271A1 (ja) *	2008-12-26	2010-07-01	武田薬品工業株式会社	糖尿病治療剤
TW201036975A (en)	2009-01-07	2010-10-16	Boehringer Ingelheim Int	Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
US20220387305A1 (en) *	2009-01-12	2022-12-08	Biokier, Inc.	Composition and method for treatment of diabetes
MY160123A (en)	2009-02-13	2017-02-28	Boehringer Ingelheim Int	Pharmaceutical composition comprising a sglt2 inhibitor, a dpp-iv inhibitor and optionally a further antidiabetic agent and uses thereof
EP2414348B1 (en)	2009-04-03	2013-11-20	Merck Sharp & Dohme Corp.	Bicyclic piperidine and piperazine derivatives as gpcr modulators for the treatment of obesity, diabetes and other metabolic disorders
CN102459222B (zh) *	2009-06-05	2014-06-04	辉瑞大药厂	用作gpr119 调节剂的l-(哌啶-4-基)-吡唑衍生物
EA201200046A1 (ru)	2009-06-24	2012-08-30	Бёрингер Ингельхайм Интернациональ Гмбх	Новые соединения, фармацевтическая композиция и связанные с ними способы
WO2010149685A1 (en)	2009-06-24	2010-12-29	Boehringer Ingelheim International Gmbh	New compounds, pharmaceutical composition and methods relating thereto
AR077642A1 (es)	2009-07-09	2011-09-14	Arena Pharm Inc	Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo
SMT201700583T1 (it) *	2009-09-28	2018-01-11	Intarcia Therapeutics Inc	Instaurazione e/o terminazione rapida di erogazione di farmaci in modo sostanzialmente stazionario
WO2011041154A1 (en)	2009-10-01	2011-04-07	Metabolex, Inc.	Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts
JP2013510834A (ja)	2009-11-16	2013-03-28	メリテク	［１，５］‐ジアゾシン誘導体
KR20240090632A (ko)	2009-11-27	2024-06-21	베링거 인겔하임 인터내셔날 게엠베하	리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
EP4148045A1 (en)	2010-01-27	2023-03-15	Arena Pharmaceuticals, Inc.	Intermediate compounds for the preparation of (r)-2-(7-(4-cyclopentyl-3- (trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b] indol-3-yl)acetic acid and salts thereof
WO2011094632A1 (en) *	2010-01-29	2011-08-04	The Uab Research Foundation	Method for administration of insulin and pharmaceutical composition thereof
WO2011113947A1 (en)	2010-03-18	2011-09-22	Boehringer Ingelheim International Gmbh	Combination of a gpr119 agonist and the dpp-iv inhibitor linagliptin for use in the treatment of diabetes and related conditions
AU2011237775A1 (en)	2010-04-06	2012-11-22	Arena Pharmaceuticals, Inc.	Modulators of the GPR119 receptor and the treatment of disorders related thereto
ES2935300T3 (es)	2010-05-05	2023-03-03	Boehringer Ingelheim Int	Combiterapia
CN109674753A (zh)	2010-06-23	2019-04-26	希玛贝治疗股份有限公司	固态分散体
MX2012014247A (es)	2010-06-24	2013-01-18	Boehringer Ingelheim Int	Terapia para la diabetes.
EA201390421A1 (ru)	2010-09-22	2013-09-30	Арена Фармасьютикалз, Инк.	Модуляторы рецептора gpr119 и лечение связанных с ним нарушений
US9034883B2 (en)	2010-11-15	2015-05-19	Boehringer Ingelheim International Gmbh	Vasoprotective and cardioprotective antidiabetic therapy
AR085689A1 (es)	2011-03-07	2013-10-23	Boehringer Ingelheim Int	Composiciones farmaceuticas de metformina, linagliptina y un inhibidor de sglt-2
US20140018371A1 (en)	2011-04-01	2014-01-16	Arena Pharmaceuticals, Inc.	Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
WO2012145361A1 (en)	2011-04-19	2012-10-26	Arena Pharmaceuticals, Inc.	Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012145604A1 (en)	2011-04-22	2012-10-26	Arena Pharmaceuticals, Inc.	Modulators of the gpr119 receptor and the treatment of disorders related thereto
US20140038889A1 (en)	2011-04-22	2014-02-06	Arena Pharmaceuticals, Inc.	Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
WO2012170702A1 (en)	2011-06-08	2012-12-13	Arena Pharmaceuticals, Inc.	Modulators of the gpr119 receptor and the treatment of disorders related thereto
ES2934843T3 (es)	2011-07-15	2023-02-27	Boehringer Ingelheim Int	Derivado de quinazolina dimérico sustituido, su preparación y su uso en composiciones farmacéuticas para el tratamiento de la diabetes de tipo I y II
WO2013055910A1 (en)	2011-10-12	2013-04-18	Arena Pharmaceuticals, Inc.	Modulators of the gpr119 receptor and the treatment of disorders related thereto
US9555001B2 (en)	2012-03-07	2017-01-31	Boehringer Ingelheim International Gmbh	Pharmaceutical composition and uses thereof
US20130303462A1 (en)	2012-05-14	2013-11-14	Boehringer Ingelheim International Gmbh	Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
EP4151218A1 (en)	2012-05-14	2023-03-22	Boehringer Ingelheim International GmbH	Linagliptin, a xanthine derivative as dpp-4 inhibitor, for use in the treatment of sirs and/or sepsis
WO2013174767A1 (en)	2012-05-24	2013-11-28	Boehringer Ingelheim International Gmbh	A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
JP2015522080A (ja)	2012-07-11	2015-08-03	エルセリクスセラピューティクスインコーポレイテッド	スタチン、ビグアナイド、およびさらなる薬剤を含む心血管代謝性リスクを減少させるための組成物
WO2014074668A1 (en)	2012-11-08	2014-05-15	Arena Pharmaceuticals, Inc.	Modulators of gpr119 and the treatment of disorders related thereto
CN103344773B (zh) *	2013-06-19	2015-04-15	天津美德太平洋科技有限公司	一种胰高血糖素样肽-1生物学活性检测试剂及检测方法和试剂盒
CN105637363B (zh)	2013-08-01	2017-06-27	庆熙大学校产学协力团	预防或治疗糖尿病的药物组合物，预防或治疗糖尿病的方法，以及筛选糖尿病治疗药物的方法
WO2015016682A1 (ko) *	2013-08-01	2015-02-05	경희대학교 산학협력단	당뇨병 예방 또는 치료용 약학적 조성물, 당뇨병 예방 또는 치료 방법, 및 당뇨병 치료제 스크리닝 방법
EP3110449B1 (en)	2014-02-28	2023-06-28	Boehringer Ingelheim International GmbH	Medical use of a dpp-4 inhibitor
EP4445956A3 (en)	2015-01-06	2024-12-04	Arena Pharmaceuticals, Inc.	Compound for use in treating conditions related to the s1p1 receptor
KR20220070057A (ko)	2015-03-09	2022-05-27	인테크린 테라퓨틱스, 아이엔씨.	비알코올성 지방간 질환 및/또는 지방이영양증의 치료 방법
PL3310760T3 (pl)	2015-06-22	2023-03-06	Arena Pharmaceuticals, Inc.	Krystaliczna sól L-argininy kwasu (R)-2-(7-(4-cyklopentylo-3-(trifluorometylo)benzyloksy)- 1,2,3,4-tetrahydrocyklo-penta[b]indol-3-ilo)octowego do zastosowania w zaburzeniach związanych z receptorem S1P1
WO2017211979A1 (en)	2016-06-10	2017-12-14	Boehringer Ingelheim International Gmbh	Combinations of linagliptin and metformin
WO2018026890A1 (en)	2016-08-03	2018-02-08	Cymabay Therapeutics	Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions
CN110520124A (zh)	2017-02-16	2019-11-29	艾尼纳制药公司	用于治疗原发性胆汁性胆管炎的化合物和方法
EP3606527A1 (en)	2017-04-03	2020-02-12	Coherus Biosciences, Inc.	Ppar-gamma agonist for treatment of progressive supranuclear palsy
JP2020524181A (ja)	2017-06-19	2020-08-13	アリーナファーマシューティカルズ，インコーポレイテッド	Ｎａｆｌｄおよびｎａｓｈの治療のための化合物および方法
CA3102136A1 (en)	2018-06-06	2019-12-12	Arena Pharmaceuticals, Inc.	Methods of treating conditions related to the s1p1 receptor
HUE071580T2 (hu)	2018-09-12	2025-09-28	Dong A St Co Ltd	Hatóanyagként GPR119 ligandumot tartalmazó gyógyszerkészítmény nem alkoholos zsírmájbetegség megelõzésében vagy kezelésében történõ alkalmazásra
US20220265652A1 (en)	2019-07-08	2022-08-25	Mankind Pharma Ltd.	Combination therapy of gpr119 agonists and dpp-4 inhibitors
WO2021182877A1 (ko) *	2020-03-11	2021-09-16	동아에스티 주식회사	당뇨 및 이에 동반하는 대사 질환의 예방 또는 치료를 위한 약학적 조성물
EP4227299A4 (en) *	2020-10-12	2025-04-09	Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd.	GLP-1 RECEPTOR AGONIST, BENZIMIDAZOLONE AND ITS USE
US20240190868A1 (en) *	2022-11-10	2024-06-13	Acerand Therapeutics (Usa) Limited	Sos1 inhibitors

Family Cites Families (286)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US751426A (en) *		1904-02-02		Safety hair-pin
US747699A (en) *	1903-09-05	1903-12-22	Achilles C Gough	Universal sanding-machine.
US4166452A (en)	1976-05-03	1979-09-04	Generales Constantine D J Jr	Apparatus for testing human responses to stimuli
US4256108A (en) *	1977-04-07	1981-03-17	Alza Corporation	Microporous-semipermeable laminated osmotic system
US4704362A (en) *	1977-11-08	1987-11-03	Genentech, Inc.	Recombinant cloning vehicle microbial polypeptide expression
US4265874A (en) *	1980-04-25	1981-05-05	Alza Corporation	Method of delivering drug with aid of effervescent activity generated in environment of use
DD296075A5 (de)	1989-08-07	1991-11-21	Martin-Luther-Universitaet Halle-Wittenberg,De	Verfahren zur herstellung neuer inhibitoren der dipeptidyl peptidase iv
CA2080474A1 (en)	1990-04-14	1991-10-15	William W. Bachovchin	Inhibitors of dipeptidyl-aminopeptidase type iv
US5462856A (en)	1990-07-19	1995-10-31	Bunsen Rush Laboratories, Inc.	Methods for identifying chemicals that act as agonists or antagonists for receptors and other proteins involved in signal transduction via pathways that utilize G-proteins
DE69231674T2 (de)	1991-10-22	2001-08-09	New England Medical Center Hospitals, Inc.	Inhibitoren der dipeptidyl-aminopeptidase vom typ-iv
MX9206628A (es)	1991-11-22	1993-05-01	Boehringer Ingelheim Pharma	Ester de prolinaboronato y metodo para su preparacion.
US6100042A (en)	1993-03-31	2000-08-08	Cadus Pharmaceutical Corporation	Yeast cells engineered to produce pheromone system protein surrogates, and uses therefor
IL111785A0 (en)	1993-12-03	1995-01-24	Ferring Bv	Dp-iv inhibitors and pharmaceutical compositions containing them
US5543396A (en)	1994-04-28	1996-08-06	Georgia Tech Research Corp.	Proline phosphonate derivatives
US20020006899A1 (en)	1998-10-06	2002-01-17	Pospisilik Andrew J.	Use of dipeptidyl peptidase IV effectors for lowering blood pressure in mammals
DE122010000020I1 (de)	1996-04-25	2010-07-08	Prosidion Ltd	Verfahren zur Senkung des Blutglukosespiegels in Säugern
AU4721897A (en)	1996-10-25	1998-05-22	Tanabe Seiyaku Co., Ltd.	Tetrahydroisoquinoline derivatives
TW492957B (en)	1996-11-07	2002-07-01	Novartis Ag	N-substituted 2-cyanopyrrolidnes
US6040145A (en)	1997-05-07	2000-03-21	Tufts University	Potentiation of the immune response
US6100234A (en)	1997-05-07	2000-08-08	Tufts University	Treatment of HIV
US6183974B1 (en) *	1997-07-31	2001-02-06	The General Hospital Corporation	Screening assays for G protein coupled receptor agonists and antagonists
JP2001518290A (ja)	1997-09-29	2001-10-16	ポイントセラピューティクス，インコーポレイテッド	インビトロでの造血細胞の刺激
CA2310400C (en)	1997-11-18	2008-02-19	Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai	Novel physiologically active substance sulphostin, process for producing the same, and use thereof
EP2433623A1 (en) *	1998-02-02	2012-03-28	Trustees Of Tufts College	Use of dipeptidylpeptidase inhibitors to regulate glucose metabolism
US5922576A (en) *	1998-02-27	1999-07-13	The John Hopkins University	Simplified system for generating recombinant adenoviruses
JP2002513762A (ja)	1998-05-04	2002-05-14	ポイントセラピューティクス，インコーポレイテッド	造血刺激
DE19823831A1 (de)	1998-05-28	1999-12-02	Probiodrug Ges Fuer Arzneim	Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
EP1084129B1 (en)	1998-06-05	2003-01-22	Point Therapeutics, Inc.	Cyclic boroproline compounds
DE19828114A1 (de) *	1998-06-24	2000-01-27	Probiodrug Ges Fuer Arzneim	Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV
DE19828113A1 (de) *	1998-06-24	2000-01-05	Probiodrug Ges Fuer Arzneim	Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV
DE19834591A1 (de)	1998-07-31	2000-02-03	Probiodrug Ges Fuer Arzneim	Verfahren zur Steigerung des Blutglukosespiegels in Säugern
WO2000010549A1 (en)	1998-08-21	2000-03-02	Point Therapeutics, Inc.	Regulation of substrate activity
DE69926007T2 (de) *	1998-10-07	2005-12-29	Medical College Of Georgia Research Institute, Inc.	Glukose-abhängiges, insulinotropisches peptid für die verwendung als osteotropes hormon
US6242422B1 (en)	1998-10-22	2001-06-05	Idun Pharmacueticals, Inc.	(Substituted)Acyl dipeptidyl inhibitors of the ice/ced-3 family of cysteine proteases
JP2003534767A (ja)	1998-11-20	2003-11-25	アリーナ・フアーマシユーチカルズ・インコーポレーテツド	ヒトオーファンｇタンパク質共役型受容体
CO5150173A1 (es)	1998-12-10	2002-04-29	Novartis Ag	Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv
JP2000191616A (ja)	1998-12-24	2000-07-11	Senju Pharmaceut Co Ltd	新規ジペプチジルアルデヒド誘導体およびそれを含有する医薬
US20030125539A1 (en) *	1999-02-22	2003-07-03	Synaptic Pharmaceutical Corporation	DNA encoding SNORF25 receptor
US6221660B1 (en) *	1999-02-22	2001-04-24	Synaptic Pharmaceutical Corporation	DNA encoding SNORF25 receptor
AU3960400A (en) *	1999-03-05	2000-09-28	Molteni L. E C. Dei Fratelli Alitti Societa' Di Esercizio S.P.A.	Use of metformin in the preparation of pharmaceutical compositions capable of inhibiting the enzyme dipeptidyl peptidase iv
GB9906715D0 (en)	1999-03-23	1999-05-19	Ferring Bv	Compositions for promoting growth
GB9906714D0 (en)	1999-03-23	1999-05-19	Ferring Bv	Compositions for improving fertility
JP4121215B2 (ja)	1999-05-17	2008-07-23	財団法人微生物化学研究会	スルフォスチン類縁体、並びにスルフォスチン及びその類縁体の製造方法
EP1187619A1 (en)	1999-05-25	2002-03-20	Point Therapeutics, Inc.	Anti-tumor agents comprising boroproline compounds
US6617340B1 (en)	1999-07-29	2003-09-09	Novartis Ag	N-(substituted glycyl)-pyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
DE19940130A1 (de)	1999-08-24	2001-03-01	Probiodrug Ges Fuer Arzneim	Neue Effektoren der Dipeptidyl Peptidase IV zur topischen Anwendung
US6653064B1 (en) *	1999-09-23	2003-11-25	Boehringer Ingelheim International Gmbh	Method for identifying compounds useful in the therapy of bone disorders
GB9923177D0 (en)	1999-09-30	1999-12-01	Pfizer Ltd	Novel polypeptide
JP2003535034A (ja)	1999-11-12	2003-11-25	ギルフォードファーマシューティカルズインコーポレイテッド	ジペプチジルペプチダーゼｉｖ阻害剤並びにジペプチジルペプチダーゼｉｖ阻害剤の製造及び使用法
US6380398B2 (en)	2000-01-04	2002-04-30	Novo Nordisk A/S	Therapeutically active and selective heterocyclic compounds that are inhibitors of the enzyme DPP-IV
EP1741445B1 (en) *	2000-01-21	2013-08-14	Novartis AG	Combinations comprising dipeptidylpeptidase-IV inhibitors and antidiabetic agents
WO2001055105A1 (en)	2000-01-24	2001-08-02	Novo Nordisk A/S	N-substituted 2-cyanopyroles and -pyrrolines which are inhibitors of the enzyme dpp-iv
US6395767B2 (en) *	2000-03-10	2002-05-28	Bristol-Myers Squibb Company	Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
US6608038B2 (en) *	2000-03-15	2003-08-19	Novartis Ag	Methods and compositions for treatment of diabetes and related conditions via gene therapy
GB0010183D0 (en)	2000-04-26	2000-06-14	Ferring Bv	Inhibitors of dipeptidyl peptidase IV
GB0010188D0 (en)	2000-04-26	2000-06-14	Ferring Bv	Inhibitors of dipeptidyl peptidase IV
PT1287133E (pt) *	2000-05-18	2007-03-30	Bayer Healthcare Ag	Regulação do receptor acoplado à proteína g tipo dopamina humano
WO2001096597A2 (en) *	2000-06-13	2001-12-20	Glaxo Group Limited	High throughput screening of compounds for biological activity
US6432969B1 (en)	2000-06-13	2002-08-13	Novartis Ag	N-(substituted glycyl)-2 cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
TW583185B (en)	2000-06-13	2004-04-11	Novartis Ag	N-(substituted glycyl)-2-cyanopyrrolidines and pharmaceutical composition for inhibiting dipeptidyl peptidase-IV (DPP-IV) or for the prevention or treatment of diseases or conditions associated with elevated levels of DPP-IV comprising the same
GB0014969D0 (en)	2000-06-19	2000-08-09	Smithkline Beecham Plc	Novel method of treatment
HUP0301622A3 (en)	2000-07-04	2006-05-29	Novo Nordisk As	Purine derivatives inhibiting the enzyme dipeptidyl petidase iv (dpp-iv) and pharmaceutical compositions containing them
AU2001277056B2 (en) *	2000-07-25	2005-09-29	Merck & Co., Inc.	N-substituted indoles useful in the treatment of diabetes
PT1308439E (pt)	2000-08-10	2008-12-12	Mitsubishi Tanabe Pharma Corp	Derivados de prolina e sua utilização como fármacos
DE60135764D1 (de)	2000-10-06	2008-10-23	Mitsubishi Tanabe Pharma Corp	Stickstoffhaltige, fünfgliedrige ringverbindungen
JP4329290B2 (ja)	2000-10-06	2009-09-09	田辺三菱製薬株式会社	脂肪族含窒素五員環化合物
JP4329291B2 (ja)	2000-10-06	2009-09-09	田辺三菱製薬株式会社	含窒素五員環化合物
JP2004035574A (ja)	2000-10-06	2004-02-05	Tanabe Seiyaku Co Ltd	脂肪族含窒素五員環化合物
AUPR107800A0 (en)	2000-10-27	2000-11-23	University Of Sydney, The	Peptide and nucleic acid molecule ii
TWI243162B (en)	2000-11-10	2005-11-11	Taisho Pharmaceutical Co Ltd	Cyanopyrrolidine derivatives
EP1364024A2 (en)	2000-11-27	2003-11-26	Arena Pharmaceuticals, Inc.	Endogenous and non-endogenous versions of human g protein-coupled receptors
JP3438186B2 (ja) *	2000-12-01	2003-08-18	山之内製薬株式会社	糖尿病治療剤スクリーニング方法
JPWO2002051836A1 (ja)	2000-12-27	2004-04-22	協和醗酵工業株式会社	ジペプチジルペプチダーゼ−ｉｖ阻害剤
CA2430967C (en)	2001-01-16	2009-06-23	Nippon Kayaku Kabushiki Kaisha	Remedies for bone marrow suppression and infectious diseases and white blood cell count elevating agents
US6397767B1 (en) *	2001-02-01	2002-06-04	Case Corporation	Knife applicator for applying liquid fertilizer in the ground
JP4213390B2 (ja)	2001-02-02	2009-01-21	武田薬品工業株式会社	縮合複素環化合物
IL157179A0 (en)	2001-02-02	2004-02-08	Takeda Chemical Industries Ltd	Fused heterocyclic compounds
SK286975B6 (sk) *	2001-02-24	2009-08-06	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Xantínové deriváty, spôsob ich výroby, farmaceutický prostriedok s ich obsahom a ich použitie
JP2002265439A (ja)	2001-03-08	2002-09-18	Mitsubishi Pharma Corp	シアノピロリジン誘導体およびその医薬用途
CN1523982A (zh) *	2001-03-27	2004-08-25	��Ǵ�ѧ��»�	减少体脂和调节脂肪酸代谢的方法、化合物和组合物
DE60226723D1 (de)	2001-03-27	2008-07-03	Merck & Co Inc	Dipeptidylpeptidase-hemmer für die behandlung oder prävention von diabetes
FR2822826B1 (fr)	2001-03-28	2003-05-09	Servier Lab	Nouveaux derives sulfonyles d'alpha-amino-acides, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
GB0109146D0 (en)	2001-04-11	2001-05-30	Ferring Bv	Treatment of type 2 diabetes
US6573287B2 (en) *	2001-04-12	2003-06-03	Bristo-Myers Squibb Company	2,1-oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase IV and method
FR2824825B1 (fr) *	2001-05-15	2005-05-06	Servier Lab	Nouveaux derives d'alpha-amino-acides, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
AU2002310465B2 (en)	2001-06-20	2006-06-15	Merck & Co., Inc.	Dipeptidyl peptidase inhibitors for the treatment of diabetes
WO2003000180A2 (en)	2001-06-20	2003-01-03	Merck & Co., Inc.	Dipeptidyl peptidase inhibitors for the treatment of diabetes
GB0115517D0 (en)	2001-06-25	2001-08-15	Ferring Bv	Novel antidiabetic agents
AU2002322344C1 (en)	2001-06-27	2006-02-16	Smithkline Beecham Corporation	Fluoropyrrolidines as dipeptidyl peptidase inhibitors
DE10154689A1 (de)	2001-11-09	2003-05-22	Probiodrug Ag	Substituierte Aminoketonverbindungen
CN1471538A (zh)	2001-06-27	2004-01-28	前体生物药物股份有限公司	用于竞争性调节二肽基肽酶iv催化的肽结构
CA2418543A1 (en)	2001-06-27	2003-01-09	Probiodrug Ag	New dipeptidyl peptidase iv inhibitors and their uses as anti-cancer agents
WO2003002553A2 (en)	2001-06-27	2003-01-09	Smithkline Beecham Corporation	Fluoropyrrolidines as dipeptidyl peptidase inhibitors
DE60223920T2 (de)	2001-06-27	2008-11-13	Smithkline Beecham Corp.	Pyrrolidine als dipeptidyl-peptidase-inhibitoren
US20030130199A1 (en) *	2001-06-27	2003-07-10	Von Hoersten Stephan	Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents
US7368421B2 (en) *	2001-06-27	2008-05-06	Probiodrug Ag	Use of dipeptidyl peptidase IV inhibitors in the treatment of multiple sclerosis
DE60225556D1 (de)	2001-07-03	2008-04-24	Novo Nordisk As	Dpp-iv-inhibierende purin-derivative zur behandlung von diabetes
US6869947B2 (en) *	2001-07-03	2005-03-22	Novo Nordisk A/S	Heterocyclic compounds that are inhibitors of the enzyme DPP-IV
UA74912C2 (en)	2001-07-06	2006-02-15	Merck & Co Inc	Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
DE10143840A1 (de)	2001-09-06	2003-03-27	Probiodrug Ag	Neue Inhibitoren der Dipeptidylpeptidase I
US6844316B2 (en) *	2001-09-06	2005-01-18	Probiodrug Ag	Inhibitors of dipeptidyl peptidase I
JPWO2003026661A1 (ja) *	2001-09-14	2005-01-06	山之内製薬株式会社	インスリン分泌促進剤及び新規なピリミジン誘導体
KR20040033048A (ko)	2001-09-14	2004-04-17	미츠비시 웰파마 가부시키가이샤	티아졸리딘 유도체 및 이의 약학적 용도
EP1463727A2 (en)	2001-09-19	2004-10-06	Novo Nordisk A/S	Heterocyclic compounds that are inhibitors of the enzyme dpp-iv
CA2463908A1 (en)	2001-10-18	2003-04-24	Bristol-Myers Squibb Company	Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
US7238671B2 (en) *	2001-10-18	2007-07-03	Bristol-Myers Squibb Company	Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
GB0125446D0 (en)	2001-10-23	2001-12-12	Ferring Bv	Novel anti-diabetic agents
GB0125445D0 (en)	2001-10-23	2001-12-12	Ferring Bv	Protease Inhibitors
US6861440B2 (en) *	2001-10-26	2005-03-01	Hoffmann-La Roche Inc.	DPP IV inhibitors
WO2003038123A2 (en)	2001-10-31	2003-05-08	Novartis Ag	Methods to treat diabetes and related conditions based on polymorphisms in the tcf1 gene
US20030125304A1 (en) *	2001-11-09	2003-07-03	Hans-Ulrich Demuth	Substituted amino ketone compounds
EP2769715A3 (en)	2001-11-26	2014-09-17	Trustees Of Tufts College	Methods for treating autoimmune disorders, and reagents related thereto
CA2837936A1 (en)	2001-11-26	2003-06-05	Trustees Of Tufts College	Peptidomimetic inhibitors of post-proline cleaving enzymes
AU2002360732A1 (en)	2001-12-26	2003-07-24	Guilford Pharmaceuticals	Change inhibitors of dipeptidyl peptidase iv
US6727261B2 (en)	2001-12-27	2004-04-27	Hoffman-La Roche Inc.	Pyrido[2,1-A]Isoquinoline derivatives
CA2475653A1 (en)	2002-02-08	2003-09-04	Idun Pharmaceuticals, Inc.	(substituted)acyl dipeptidyl inhibitors of the ice/ced-3 family of cysteine proteases
KR100608414B1 (ko) *	2002-02-13	2006-08-02	에프. 호프만-라 로슈 아게	신규한 피리딘- 및 피리미딘-유도체
CA2474460C (en)	2002-02-13	2009-12-22	F. Hoffmann-La Roche Ag	Pyridine- and quinoline-derivatives
US6906074B2 (en)	2002-02-22	2005-06-14	Nippon Zoki Pharmaceutical Co., Ltd.	2-phenylpiperazine derivatives
JP2004043429A (ja)	2002-02-25	2004-02-12	Eisai Co Ltd	新規キサンチン誘導体およびｄｐｐｉｖ阻害剤
EP1338595B1 (en) *	2002-02-25	2006-05-03	Eisai Co., Ltd.	Xanthine derivatives as DPP-IV inhibitors
EP1480961B1 (en) *	2002-02-28	2006-12-27	Prosidion Ltd.	Glutaminyl based dpiv inhibitors
HUP0200849A2 (hu)	2002-03-06	2004-08-30	Sanofi-Synthelabo	N-aminoacetil-2-ciano-pirrolidin-származékok, e vegyületeket tartalmazó gyógyszerkészítmények és eljárás előállításukra
DE60322857D1 (de)	2002-03-25	2008-09-25	Nippon Kayaku Kk	Neues alpha-amino-n-(diaminophosphinyl)lactamderivat
ATE373660T1 (de)	2002-03-25	2007-10-15	Merck & Co Inc	Heterocyclische beta-aminoverbindungen als inhibitoren der dipeptidylpeptidase zur behandlung bzw. prävention von diabetes
JP4329381B2 (ja)	2002-04-04	2009-09-09	田辺三菱製薬株式会社	医薬組成物
JP4329382B2 (ja)	2002-04-04	2009-09-09	田辺三菱製薬株式会社	医薬組成物
CA2481995A1 (en)	2002-04-08	2003-10-16	Torrent Pharmaceuticals Ltd.	Thiazolidine-4-carbonitriles and analogues and their use as dipeptidyl-peptidas inhibitors
JP2003300977A (ja)	2002-04-10	2003-10-21	Sumitomo Pharmaceut Co Ltd	キサンチン誘導体
AU2003235913A1 (en)	2002-05-09	2003-11-11	Taisho Pharmaceutical Co., Ltd.	Cyanopyrrolidine derivatives
JP2004026820A (ja)	2002-05-09	2004-01-29	Taisho Pharmaceut Co Ltd	ジペプチジルペプチダーゼｉｖ阻害剤
JP2003327532A (ja)	2002-05-10	2003-11-19	Takeda Chem Ind Ltd	ペプチダーゼ阻害剤
GB0212412D0 (en)	2002-05-29	2002-07-10	Novartis Ag	Combination of organic compounds
KR20050012771A (ko)	2002-06-03	2005-02-02	노파르티스 아게	치환된 시아노피롤리딘의 용도 및 이들을 함유하는고지혈증 및 관련 질환의 치료를 위한 조합 제제
US6710040B1 (en)	2002-06-04	2004-03-23	Pfizer Inc.	Fluorinated cyclic amides as dipeptidyl peptidase IV inhibitors
WO2003101449A2 (en)	2002-06-04	2003-12-11	Pfizer Products Inc.	Process for the preparation of 3,3,4,4-tetrafluoropyrrolidine and derivatives thereof
BR0311608A (pt)	2002-06-04	2005-02-22	Pfizer Prod Inc	Amidas cìclicas fluoradas como inibidores da dipeptidil-peptidase iv
PL374007A1 (en) *	2002-06-06	2005-09-19	Eisai Co, Ltd.	Novel fused imidazole derivative
HUP0202001A2 (hu)	2002-06-14	2005-08-29	Sanofi-Aventis	DDP-IV gátló hatású azabiciklooktán- és nonánszármazékok
JP2004026678A (ja)	2002-06-24	2004-01-29	Microbial Chem Res Found	２型糖尿病治療剤
IL166156A0 (en)	2002-07-09	2006-01-15	Point Therapeutics Inc	Boroproline compound combination therapy
JPWO2004007446A1 (ja)	2002-07-10	2005-11-10	アステラス製薬株式会社	新規なアゼチジン誘導体又はその塩
US7208498B2 (en) *	2002-07-15	2007-04-24	Merck & Co., Inc.	Piperidino pyrimidine dipeptidyl peptidase inhibitors for the treatment of diabetes
TW200401635A (en)	2002-07-23	2004-02-01	Yamanouchi Pharma Co Ltd	2-Cyano-4-fluoropyrrolidine derivative or salt thereof
JP4542757B2 (ja)	2002-08-08	2010-09-15	武田薬品工業株式会社	縮合複素環化合物
DE60322224D1 (de)	2002-08-08	2008-08-28	Takeda Pharmaceutical	Kondensierte heterozyklische verbindungen als petidase inhibitoren
DE10236667B4 (de) *	2002-08-09	2007-06-06	J. Eberspächer GmbH & Co. KG	Abgasanlage für den Verbrennungsmotor eines Kraftfahrzeugs
US20050101542A1 (en) *	2002-08-20	2005-05-12	Regents Of The University Of California	Combination therapy for controlling appetites
KR101150449B1 (ko)	2002-08-21	2012-06-01	베링거 잉겔하임 파르마 게엠베하 운트 코 카게	8-［3-아미노-피페리딘-1-일］-크산틴, 이의 제조방법 및 이를 포함하는 약제학적 조성물
DE10238243A1 (de)	2002-08-21	2004-03-04	Boehringer Ingelheim Pharma Gmbh & Co. Kg	8-[3-Amino-piperidin-1-yl]-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
US7407955B2 (en) *	2002-08-21	2008-08-05	Boehringer Ingelheim Pharma Gmbh & Co., Kg	8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
DE10238470A1 (de)	2002-08-22	2004-03-04	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel
DE10238477A1 (de)	2002-08-22	2004-03-04	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Neue Purinderivate, deren Herstellung und deren Verwendung als Arzneimittel
EP1535907A4 (en)	2002-08-29	2006-11-29	Taisho Pharmaceutical Co Ltd	BENZOLSULFONATE OF A 4-FLUORO-2-CYANOPYRROLIDINE DERIVATIVE
EP1537880A4 (en) *	2002-09-11	2009-07-01	Takeda Pharmaceutical	Sustained release preparation
EP1538217A4 (en) *	2002-09-11	2006-09-27	Astellas Pharma Inc	SCREENING METHOD FOR INSULATION STOP ENHANCER
DE60315687T2 (de)	2002-10-07	2008-06-05	Merck & Co., Inc.	Antidiabetische heterocyclische beta-aminoverbindungen als inhibitoren von dipeptidylpeptidase
AU2003269850A1 (en)	2002-10-08	2004-05-04	Novo Nordisk A/S	Hemisuccinate salts of heterocyclic dpp-iv inhibitors
AR041470A1 (es) *	2002-10-17	2005-05-18	Upjohn Co	Compuestos de pirrolo (1,2 - b) piridazina y sus usos
ES2301879T3 (es)	2002-10-18	2008-07-01	MERCK & CO., INC.	Inhibidores de dipeptidilpeptidasa heterociclica beta-amino para el tratamiento o prevencion de diabetes.
US6995180B2 (en)	2002-10-23	2006-02-07	Bristol Myers Squibb Company	Glycinenitrile-based inhibitors of dipeptidyl peptidase IV and methods
WO2004041795A1 (en)	2002-10-30	2004-05-21	Guilford Pharmaceuticals Inc.	Novel inhibitors of dipeptidyl peptidase iv
WO2004048379A1 (ja)	2002-11-01	2004-06-10	Sumitomo Pharmaceuticals Co., Ltd.	キサンチン化合物
PL376822A1 (pl)	2002-11-07	2006-01-09	Merck & Co., Inc.	Pochodne fenyloalaniny jako inhibitory dipeptydylopeptydazy do leczenia lub zapobiegania cukrzycy
US7482337B2 (en) *	2002-11-08	2009-01-27	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
DE10251927A1 (de)	2002-11-08	2004-05-19	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel
EP1565437A1 (en)	2002-11-18	2005-08-24	Pfizer Products Inc.	Dipeptidyl peptidase iv inhibiting fluorinated cyclic amides
DE10256264A1 (de)	2002-12-03	2004-06-24	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Neue substituierte Imidazo-pyridinone und Imidazo-pyridazinone, ihre Herstellung und ihre Verwendung als Arzneimittel
UY28103A1 (es)	2002-12-03	2004-06-30	Boehringer Ingelheim Pharma	Nuevas imidazo-piridinonas sustituidas, su preparación y su empleo como medicacmentos
US7309714B2 (en) *	2002-12-04	2007-12-18	Merck & Co., Inc.	Phenylalanine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
US7420079B2 (en)	2002-12-09	2008-09-02	Bristol-Myers Squibb Company	Methods and compounds for producing dipeptidyl peptidase IV inhibitors and intermediates thereof
CA2505771A1 (en)	2002-12-10	2004-06-24	Novartis Ag	Combination of an dpp-iv inhibitor and a ppar-alpha compound
CA2508947A1 (en) *	2002-12-20	2004-07-15	Merck & Co., Inc.	3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
US6982164B2 (en) *	2003-01-10	2006-01-03	Mgp Ingredients, Inc.	Unhydrolyzed jojoba protein products having high simmondsin concentration
CN102558155A (zh)	2003-01-14	2012-07-11	阿伦纳药品公司	作为代谢调节剂的芳基和杂芳基衍生物及其所涉及的疾病如糖尿病和高血糖症的预防和治疗
CA2512546A1 (en)	2003-01-17	2004-08-05	Merck & Co., Inc.	3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
JP2004244412A (ja)	2003-01-20	2004-09-02	Kotobuki Seiyaku Kk	４位に置換基を有する２−シアノピロリジン誘導体及びその製造方法並びにそれを含有する薬剤
AU2004210149A1 (en) *	2003-01-31	2004-08-19	Merck & Co., Inc.	3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
JP4184378B2 (ja)	2003-01-31	2008-11-19	株式会社三和化学研究所	ジペプチジルペプチダーゼｉｖを阻害する化合物
WO2004071454A2 (en)	2003-02-13	2004-08-26	Guilford Pharmaceuticals Inc.	Substituted azetidine compounds as inhibitors of dipeptidyl peptidase iv
ES2316964T3 (es) *	2003-02-24	2009-04-16	Arena Pharmaceuticals, Inc.	Fenil-y piridilpipereidinia-derivados como moduladores del metabolismo de la glucosa.
WO2004076434A1 (en)	2003-02-28	2004-09-10	Aic	Dipeptidyl peptidase inhibitors
WO2004076433A1 (en)	2003-02-28	2004-09-10	Aic	Dipeptidyl peptidase inhibitors
JP2004269468A (ja)	2003-03-12	2004-09-30	Yamanouchi Pharmaceut Co Ltd	ピリミジン誘導体又はその塩
JP2004269469A (ja)	2003-03-12	2004-09-30	Yamanouchi Pharmaceut Co Ltd	ピリミジン誘導体又はその塩
AR043515A1 (es)	2003-03-19	2005-08-03	Merck & Co Inc	Procedimiento para preparar derivados quirales beta aminoacidos mediante hidrogenacion asimetrica
WO2004085661A2 (en)	2003-03-24	2004-10-07	Merck & Co., Inc	Process to chiral beta-amino acid derivatives
US7550590B2 (en)	2003-03-25	2009-06-23	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
WO2004087650A2 (en)	2003-03-27	2004-10-14	Merck & Co. Inc.	Process and intermediates for the preparation of beta-amino acid amide dipeptidyl peptidase-iv inhibitors
WO2004092128A1 (en)	2003-04-10	2004-10-28	Smithkline Beecham Corporation	Anhydrous crystalline forms of (2s, 4s)-1-{(2r)-2-amino-3-‘4-methoxybenzyl)sulfonyl!-3-methylbutanoyl}-4-fluoropyrrolindine-2-carbonitrile
WO2004096806A1 (ja)	2003-04-30	2004-11-11	Sumitomo Pharmaceuticals Co. Ltd.	縮合イミダゾール誘導体
DE602004026289D1 (de) *	2003-05-05	2010-05-12	Probiodrug Ag	Glutaminylcyclase-hemmer
WO2004099134A2 (en)	2003-05-05	2004-11-18	Prosidion Ltd.	Glutaminyl based dp iv-inhibitors
US7083933B1 (en)	2003-05-09	2006-08-01	Prosidion Limited	Methods for identification of modulators of OSGPR116 activity
CA2524531A1 (en)	2003-05-14	2004-12-02	Merck And Co., Inc.	3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
EP1625122A1 (en)	2003-05-14	2006-02-15	Takeda San Diego, Inc.	Dipeptidyl peptidase inhibitors
AU2004238719A1 (en)	2003-05-15	2004-11-25	Taisho Pharmaceutical Co., Ltd.	Cyanofluoropyrrolidine derivative
WO2004104215A2 (en)	2003-05-21	2004-12-02	Bayer Healthcare Ag	Diagnostics and therapeutics for diseases associated with dipeptidylpeptidase 7 (dpp7)
WO2004104216A2 (en)	2003-05-21	2004-12-02	Bayer Healthcare Ag	Diagnostics and therapeutics for diseases associated with dipeptidylpeptidase iv (dpp4)
AU2003902828A0 (en)	2003-06-05	2003-06-26	Fujisawa Pharmaceutical Co., Ltd.	Dpp-iv inhibitor
CA2526770A1 (en)	2003-06-06	2004-12-23	Merck & Co., Inc.	Fused indoles as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
US20070099884A1 (en)	2003-06-06	2007-05-03	Erondu Ngozi E	Combination therapy for the treatment of diabetes
AU2003902946A0 (en)	2003-06-12	2003-06-26	Fujisawa Pharmaceutical Co., Ltd.	Dpp-iv inhibitor
AU2004249163A1 (en)	2003-06-17	2004-12-29	Merck & Co., Inc.	Cyclohexylglycine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
DE10327439A1 (de)	2003-06-18	2005-01-05	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Neue Imidazopyridazinon- und Imidazopyridonderivate, deren Herstellung und deren Verwendung als Arzneimittel
EP1638968B1 (en)	2003-06-20	2009-07-29	F.Hoffmann-La Roche Ag	Hexahydropyridoisoqinolines as dpp-iv inhibitors
RS52397B (sr)	2003-06-20	2013-02-28	F.Hoffmann-La Roche Ag	Derivati pirido /2,1-a/izohinolina kao dpp-iv inhibitori
JO2625B1 (en) *	2003-06-24	2011-11-01	ميرك شارب اند دوم كوربوريشن	Phosphoric acid salts of dipeptidyl betidase inhibitor 4
JP2005023038A (ja)	2003-07-04	2005-01-27	Taisho Pharmaceut Co Ltd	慢性腎疾患治療薬
AR045047A1 (es) *	2003-07-11	2005-10-12	Arena Pharm Inc	Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
AU2004257267B2 (en) *	2003-07-14	2009-12-03	Arena Pharmaceuticals,Inc	Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
DE602004017325D1 (de)	2003-07-21	2008-12-04	Smithkline Beecham Corp	(2s,4s)-4-fluor-1-ä4-fluor-beta-(4-fluorphenyl)-l-phenylalanylü-2-pyrrolidincarbonitril-p-toluolsulfonsäuresalz und wasserfreie kristalline formen davon
US7094800B2 (en) *	2003-07-25	2006-08-22	Sanofi-Aventis Deutschland Gmbh	Cyanopyrrolidides, process for their preparation and their use as medicaments
US7008957B2 (en) *	2003-07-25	2006-03-07	Sanofi-Aventis Deutschland Gmbh	Bicyclic cyanoheterocycles, process for their preparation and their use as medicaments
PE20050249A1 (es)	2003-07-25	2005-06-01	Aventis Pharma Gmbh	Nuevas cianopirrolididas y procedimiento para su preparacion como medicamentos
DE10333935A1 (de)	2003-07-25	2005-02-24	Aventis Pharma Deutschland Gmbh	Neue bicyclische Cyanoheterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP1651623B1 (en)	2003-07-31	2008-12-17	Merck & Co., Inc.	Hexahydrodiazepinones as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
US6995183B2 (en)	2003-08-01	2006-02-07	Bristol Myers Squibb Company	Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods
WO2005019168A2 (en)	2003-08-20	2005-03-03	Pfizer Products Inc.	Fluorinated lysine derivatives as dipeptidyl peptidase iv inhibitors
HU227684B1 (en)	2003-08-29	2011-11-28	Sanofi Aventis	Adamantane and azabicyclo-octane and nonane derivatives and their use as dpp-iv inhibitors
EP1659123A1 (en)	2003-08-29	2006-05-24	Dainippon Sumitomo Pharma Co., Ltd.	Bicyclic pyrazole derivative
JP2007504230A (ja)	2003-09-02	2007-03-01	メルク　エンド　カムパニー　インコーポレーテッド	ジペプチジルペプチダーゼ−ｉｖ阻害剤のリン酸塩の新規結晶性形態
WO2005023762A1 (en)	2003-09-04	2005-03-17	Abbott Laboratories	Pyrrolidine-2-carbonitrile derivatives and their use as inhibitors of dipeptidyl peptidase-iv (dpp-iv)
JP2007513058A (ja)	2003-09-08	2007-05-24	武田薬品工業株式会社	ジペプチジルぺプチダーゼ阻害剤
JP2007505121A (ja)	2003-09-08	2007-03-08	武田薬品工業株式会社	ジペプチジルぺプチダーゼ阻害剤
PE20050948A1 (es)	2003-09-09	2005-12-16	Japan Tobacco Inc	Compuestos de carbamoil-amina como inhibidores de la dipeptidil peptidasa iv
WO2005030127A2 (en)	2003-09-23	2005-04-07	Merck & Co., Inc.	Novel crystalline form of a phosphoric acid salt of a dipeptidyl peptidase-iv inhibitor
WO2005033099A2 (en)	2003-10-03	2005-04-14	Glenmark Pharmaceuticals Ltd.	Novel dipeptidyl peptidase iv inhibitors; processes for their preparation and compositions thereof
WO2005032590A1 (ja)	2003-10-03	2005-04-14	Takeda Pharmaceutical Company Limited	糖尿病治療剤
DE10348044A1 (de)	2003-10-15	2005-05-19	Imtm Gmbh	Duale Alanyl-Aminopeptidase- und Dipeptidylpeptidase IV-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen
DE10348022A1 (de)	2003-10-15	2005-05-25	Imtm Gmbh	Neue Dipeptidylpeptidase IV-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen
GB0324236D0 (en)	2003-10-16	2003-11-19	Astrazeneca Ab	Chemical compounds
TW200519105A (en)	2003-10-20	2005-06-16	Lg Life Science Ltd	Novel inhibitors of DPP-IV, methods of preparing the same, and pharmaceutical compositions containing the same as an active agent
PE20050444A1 (es)	2003-10-31	2005-08-09	Takeda Pharmaceutical	Compuestos de piridina como inhibidores de la peptidasa
JP2007510651A (ja)	2003-11-04	2007-04-26	メルク　エンド　カムパニー　インコーポレーテッド	糖尿病の治療又は予防のためのジペプチジルペプチダーゼ−ｉｖ阻害剤としての縮合フェニルアラニン誘導体
WO2005047297A1 (en)	2003-11-12	2005-05-26	Phenomix Corporation	Heterocyclic boronic acid compounds
CA2545641A1 (en)	2003-11-17	2005-06-02	Novartis Ag	Use of organic compounds
DE10355304A1 (de) *	2003-11-27	2005-06-23	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Neue 8-(Piperazin-1-yl)-und 8-([1,4]Diazepan-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
WO2005058849A1 (en)	2003-12-15	2005-06-30	Glenmark Pharmaceuticals Ltd.	New dipeptidyl peptidase in inhibitors; process for their preparation and compositions containing them
US7217711B2 (en) *	2003-12-17	2007-05-15	Boehringer Ingelheim International Gmbh	Piperazin-1-yl and 2-([1,4]diazepan-1-yl)-imidazo[4,5-d]-pyridazin-4-ones, the preparation thereof and their use as pharmaceutical compositions
DE10360835A1 (de)	2003-12-23	2005-07-21	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Bicyclische Imidazolverbindungen, deren Herstellung und deren Verwendung als Arzneimittel
JP4958560B2 (ja) *	2003-12-24	2012-06-20	プロシディオン・リミテッド	Ｇｐｃｒ受容体作動薬としてのヘテロ環誘導体
EP1708571A4 (en)	2004-01-16	2009-07-08	Merck & Co Inc	NEW CRYSTALLINE SALTS OF A DIPEPTIDYLPEPTIDASE IV HEMMER
WO2005075426A1 (en)	2004-02-03	2005-08-18	Glenmark Pharmaceuticals Ltd.	Novel dipeptidyl peptidase iv inhibitors; processes for their preparation and compositions thereof
US7501426B2 (en) *	2004-02-18	2009-03-10	Boehringer Ingelheim International Gmbh	8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
US20090017015A1 (en)	2004-02-20	2009-01-15	Thomas Edward Hughes	Dpp-iv inhibitors for treating neurodegeneration and cognitive disorders
EP1732885A1 (en)	2004-02-23	2006-12-20	Trustees Of Tufts College	Lactams as conformationally constrained peptidomimetic inhibitors
DE102004009039A1 (de) *	2004-02-23	2005-09-08	Boehringer Ingelheim Pharma Gmbh & Co. Kg	8-[3-Amino-piperidin-1-yl]-xanthine, deren Herstellung und Verwendung als Arzneimittel
US20050203027A1 (en)	2004-02-23	2005-09-15	Trustees Of Tufts College	Inhibitors of dipeptidylpeptidase IV
US7687504B2 (en)	2004-03-09	2010-03-30	National Health Research Institutes	Pyrrolidine compounds
PT1756084E (pt) *	2004-06-04	2009-02-17	Arena Pharm Inc	Composto seleccionado de compostos de fórmula (i) e seus sais, solvatos, hidratos e n-óxidos farmaceuticamente aceitáveis
US20060024313A1 (en) *	2004-07-06	2006-02-02	Xin Chen	Agents that disrupt dimer formation in DPP-IV family of prolyl dipeptidases
WO2006019965A2 (en) *	2004-07-16	2006-02-23	Takeda San Diego, Inc.	Dipeptidyl peptidase inhibitors
DE102004037554A1 (de)	2004-08-03	2006-03-16	Sanofi-Aventis Deutschland Gmbh	Substituierte 8-Aminoalkylthio-xanthine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102004038268A1 (de)	2004-08-06	2006-03-16	Sanofi-Aventis Deutschland Gmbh	Substituierte, bizyklische 8-Pyrrolidino-xanthine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US20060046978A1 (en) *	2004-08-31	2006-03-02	Morphochem Ag	Novel compounds that inhibit dipeptidyl peptidase (DPP-IV) and neprilysin (NEP) and/or angiotensin converting enzyme (ACE)
DE102004043944A1 (de)	2004-09-11	2006-03-30	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Neue 8-(3-Amino-piperidin-1-yl)-7-(but-2-inyl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
DE102004044221A1 (de) *	2004-09-14	2006-03-16	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Neue 3-Methyl-7-butinyl-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
WO2006041797A2 (en) *	2004-10-07	2006-04-20	Merck & Co., Inc.	Acyclic hydrazides as cannabinoid receptor modulators
WO2006047248A1 (en) *	2004-10-25	2006-05-04	Novartis Ag	Combination of dpp-iv inhibitor, ppar antidiabetic and metformin
US7411093B2 (en) *	2004-12-20	2008-08-12	Hoffman-La Roche Inc.	Aminocycloalkanes as DPP-IV inhibitors
EP1828192B1 (en) *	2004-12-21	2014-12-03	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
MX2007007483A (es)	2004-12-24	2007-07-20	Dainippon Sumitomo Pharma Co	Derivados de pirroles biciclicos.
US7589088B2 (en) *	2004-12-29	2009-09-15	Bristol-Myers Squibb Company	Pyrimidine-based inhibitors of dipeptidyl peptidase IV and methods
MY148521A (en)	2005-01-10	2013-04-30	Arena Pharm Inc	Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
DOP2006000008A (es) *	2005-01-10	2006-08-31	Arena Pharm Inc	Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
WO2006086727A2 (en) *	2005-02-09	2006-08-17	Entelos, Inc.	Treating diabetes with glucagon-like peptide-1 secretagogues
WO2007027225A2 (en) *	2005-04-27	2007-03-08	Arena Pharmaceuticals, Inc.	Combination therapy for the treatment of obesity and diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood glp-1 level
WO2006132406A1 (ja)	2005-06-09	2006-12-14	Banyu Pharmaceutical Co., Ltd.	下痢を伴う疾患の治療剤としてのnpy y2アゴニスト
US20090221644A1 (en) *	2005-06-30	2009-09-03	Stuart Edward Bradley	Gpcr Agonists
US20090325924A1 (en) *	2005-06-30	2009-12-31	Stuart Edward	GPCR Agonists
JP2008545010A (ja) *	2005-06-30	2008-12-11	プロシディオン・リミテッド	Ｇタンパク質共役受容体アゴニスト
US7708191B2 (en) *	2005-07-28	2010-05-04	Edwin Vega	Telebanking apparatus for transferring money or cash value between two parties in the same country or across national borders, for paying bills and browsing the internet
JP4827483B2 (ja) *	2005-10-04	2011-11-30	キヤノン株式会社	核酸試料処理装置
CN103536924A (zh) *	2006-04-11	2014-01-29	艾尼纳制药公司	使用gpr119受体鉴定可用于增加个体骨质量的化合物的方法
PE20071221A1 (es) *	2006-04-11	2007-12-14	Arena Pharm Inc	Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
US8222261B2 (en) *	2006-07-13	2012-07-17	GlaxoSmithKline, LLC	Chemical compounds
CA2661371A1 (en) *	2006-08-30	2008-03-06	Biovitrum Ab (Publ)	Pyrimidine compounds for treating gpr119 related disorders
MY157365A (en) *	2006-12-06	2016-05-31	Smithkline Beecham Corp	Chemical compounds and uses
CA2672059A1 (en) *	2006-12-14	2008-06-26	Merck & Co., Inc.	Acyl bipiperidinyl compounds, compositions containing such compounds and methods of treatment
US20090270404A1 (en) *	2008-03-31	2009-10-29	Metabolex, Inc.	Oxymethylene aryl compounds and uses thereof
EP2108960A1 (en) *	2008-04-07	2009-10-14	Arena Pharmaceuticals, Inc.	Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditons modulated by PYY
WO2009150144A1 (en) *	2008-06-10	2009-12-17	Inovacia Ab	New gpr119modulators
BRPI0919288A2 (pt) *	2008-09-10	2015-12-15	Boehring Ingelheim Internat Gmbh	teriapia de combinação para tratamento de diabetes e condições relacionadas.
WO2010074271A1 (ja) *	2008-12-26	2010-07-01	武田薬品工業株式会社	糖尿病治療剤
US20140193463A1 (en) *	2013-01-04	2014-07-10	China Medical University	Peptide for inhibiting dipeptidyl-peptidase iv

2006
- 2006-01-05 DO DO2006000008A patent/DOP2006000008A/es unknown
- 2006-01-06 PE PE2010000178A patent/PE20100398A1/es not_active Application Discontinuation
- 2006-01-06 GT GT200600004A patent/GT200600004A/es unknown
- 2006-01-06 PE PE2006000045A patent/PE20061116A1/es not_active Application Discontinuation
- 2006-01-09 WO PCT/US2006/000510 patent/WO2006076231A2/en not_active Ceased
- 2006-01-09 KR KR1020137032119A patent/KR20130140226A/ko not_active Ceased
- 2006-01-09 AU AU2006205164A patent/AU2006205164B2/en not_active Ceased
- 2006-01-09 KR KR1020107010978A patent/KR101016890B1/ko not_active Expired - Fee Related
- 2006-01-09 EP EP10010819A patent/EP2322151A3/en not_active Withdrawn
- 2006-01-09 DK DK06717678.4T patent/DK1758565T4/da active
- 2006-01-09 EP EP08009893A patent/EP1997484A3/en not_active Withdrawn
- 2006-01-09 KR KR1020107023765A patent/KR20100129328A/ko not_active Ceased
- 2006-01-09 US US11/328,405 patent/US20060154866A1/en not_active Abandoned
- 2006-01-09 MX MX2007008376A patent/MX2007008376A/es active IP Right Grant
- 2006-01-09 EP EP10010818A patent/EP2322150A3/en not_active Withdrawn
- 2006-01-09 NZ NZ578504A patent/NZ578504A/en not_active IP Right Cessation
- 2006-01-09 PT PT06717678T patent/PT1758565E/pt unknown
- 2006-01-09 EP EP10010820A patent/EP2322152A1/en not_active Withdrawn
- 2006-01-09 BR BRPI0606727-1A patent/BRPI0606727A/pt not_active IP Right Cessation
- 2006-01-09 TW TW095100807A patent/TW200637534A/zh unknown
- 2006-01-09 EP EP10010656A patent/EP2322156A1/en not_active Withdrawn
- 2006-01-09 EP EP07004743A patent/EP1808168B1/en not_active Revoked
- 2006-01-09 PL PL07004743T patent/PL1808168T3/pl unknown
- 2006-01-09 EP EP09006268A patent/EP2116235A1/en not_active Withdrawn
- 2006-01-09 SI SI200630363T patent/SI1808168T1/sl unknown
- 2006-01-09 AR ARP060100072A patent/AR052082A1/es unknown
- 2006-01-09 CN CN201310606771.0A patent/CN103611161A/zh active Pending
- 2006-01-09 SI SI200630362T patent/SI1758565T1/sl unknown
- 2006-01-09 CA CA2593427A patent/CA2593427C/en not_active Expired - Fee Related
- 2006-01-09 HN HN2006000971A patent/HN2006000971A/es unknown
- 2006-01-09 AT AT06717678T patent/ATE431139T1/de active
- 2006-01-09 RS RSP-2009/0366A patent/RS51174B/sr unknown
- 2006-01-09 KR KR1020127029863A patent/KR20120139849A/ko not_active Withdrawn
- 2006-01-09 ES ES06717678T patent/ES2327268T5/es not_active Expired - Lifetime
- 2006-01-09 SG SG201000208-7A patent/SG158876A1/en unknown
- 2006-01-09 ES ES07004743T patent/ES2327872T3/es not_active Expired - Lifetime
- 2006-01-09 DK DK07004743T patent/DK1808168T3/da active
- 2006-01-09 DE DE602006006765T patent/DE602006006765D1/de not_active Expired - Lifetime
- 2006-01-09 EP EP06717678A patent/EP1758565B2/en not_active Expired - Lifetime
- 2006-01-09 SG SG2013026273A patent/SG189762A1/en unknown
- 2006-01-09 PT PT07004743T patent/PT1808168E/pt unknown
- 2006-01-09 DE DE602006007093T patent/DE602006007093D1/de not_active Expired - Lifetime
- 2006-01-09 CA CA2654733A patent/CA2654733C/en not_active Expired - Fee Related
- 2006-01-09 PL PL06717678T patent/PL1758565T5/pl unknown
- 2006-01-09 KR KR1020077018318A patent/KR20070095400A/ko not_active Ceased
- 2006-01-09 HR HRP20090403TT patent/HRP20090403T4/hr unknown
- 2006-01-09 NZ NZ578502A patent/NZ578502A/en not_active IP Right Cessation
- 2006-01-09 JP JP2007550512A patent/JP4118323B1/ja not_active Expired - Fee Related
- 2006-01-09 EA EA200701469A patent/EA011883B1/ru not_active IP Right Cessation
- 2006-01-09 RS RSP-2009/0354A patent/RS51127B/sr unknown
- 2006-01-09 CN CN2011100978256A patent/CN102218141A/zh active Pending
- 2006-01-09 EP EP10010659A patent/EP2322157A1/en not_active Withdrawn
- 2006-01-09 NZ NZ587368A patent/NZ587368A/en not_active IP Right Cessation
- 2006-01-09 AT AT07004743T patent/ATE432693T1/de active
- 2006-01-09 NZ NZ556219A patent/NZ556219A/en not_active IP Right Cessation
- 2006-01-10 PA PA20068659301A patent/PA8659301A1/es unknown
- 2006-11-22 US US11/603,417 patent/US7803754B2/en not_active Expired - Fee Related
- 2006-11-22 US US11/603,410 patent/US7803753B2/en not_active Expired - Fee Related
2007
- 2007-07-02 CR CR9220A patent/CR9220A/es not_active Application Discontinuation
- 2007-07-02 IL IL184364A patent/IL184364A0/en unknown
- 2007-07-09 NI NI200700174A patent/NI200700174A/es unknown
- 2007-07-20 NO NO20073816A patent/NO331089B1/no not_active IP Right Cessation
- 2007-09-06 JP JP2007232094A patent/JP4787804B2/ja not_active Expired - Fee Related
2008
- 2008-03-17 JP JP2008068596A patent/JP4807887B2/ja not_active Expired - Fee Related
- 2008-03-17 JP JP2008068597A patent/JP4221444B2/ja not_active Expired - Fee Related
- 2008-03-17 JP JP2008068598A patent/JP4237243B2/ja not_active Expired - Fee Related
- 2008-04-16 JP JP2008107320A patent/JP4912349B2/ja not_active Expired - Fee Related
2009
- 2009-07-17 AU AU2009202898A patent/AU2009202898B2/en not_active Ceased
- 2009-07-17 AU AU2009202900A patent/AU2009202900B8/en not_active Ceased
- 2009-08-03 CY CY20091100816T patent/CY1109260T1/el unknown
- 2009-08-19 CY CY20091100881T patent/CY1109321T1/el unknown
- 2009-08-20 HR HR20090446T patent/HRP20090446T1/hr unknown
- 2009-10-30 US US12/609,599 patent/US20100137293A1/en not_active Abandoned
- 2009-11-02 US US12/610,674 patent/US8030270B2/en not_active Expired - Fee Related
- 2009-11-02 US US12/610,639 patent/US8198232B2/en not_active Expired - Fee Related
- 2009-11-02 US US12/610,877 patent/US8022034B2/en not_active Expired - Fee Related
- 2009-11-02 US US12/610,885 patent/US20100286168A1/en not_active Abandoned
- 2009-11-02 US US12/610,918 patent/US20100286153A1/en not_active Abandoned
- 2009-11-02 US US12/610,967 patent/US20100298333A1/en not_active Abandoned
- 2009-11-02 US US12/610,490 patent/US20100285494A1/en not_active Abandoned
- 2009-11-02 US US12/610,682 patent/US8003597B2/en not_active Expired - Fee Related
2010
- 2010-05-31 CL CL2010000565A patent/CL2010000565A1/es unknown
- 2010-12-09 NO NO20101746A patent/NO20101746L/no not_active Application Discontinuation
2011
- 2011-02-01 DO DO2011000040A patent/DOP2011000040A/es unknown
- 2011-06-07 JP JP2011127707A patent/JP2011184458A/ja not_active Withdrawn
- 2011-08-05 JP JP2011172381A patent/JP2012017330A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
CA2593427C (en)	2011-11-29
EP1997484A3 (en)	2009-02-11
HRP20090403T4 (hr)	2012-12-31
EP2322152A1 (en)	2011-05-18
JP4237243B2 (ja)	2009-03-11
SI1758565T1 (sl)	2009-10-31
SG189762A1 (en)	2013-05-31
EA011883B1 (ru)	2009-06-30
US20100286172A1 (en)	2010-11-11
CA2593427A1 (en)	2006-07-20
DK1808168T3 (da)	2009-10-05
PL1758565T3 (pl)	2009-10-30
SG158876A1 (en)	2010-02-26
HK1096537A1 (en)	2007-06-01
WO2006076231A8 (en)	2006-09-21
IL184364A0 (en)	2007-10-31
DOP2011000040A (es)	2011-09-30
RS51174B (sr)	2010-10-31
EP2322157A1 (en)	2011-05-18
US8022034B2 (en)	2011-09-20
JP4807887B2 (ja)	2011-11-02
JP4221444B2 (ja)	2009-02-12
DE602006006765D1 (de)	2009-06-25
CA2654733C (en)	2011-09-06
AU2009202900B8 (en)	2010-06-03
JP2008220375A (ja)	2008-09-25
GT200600004A (es)	2006-09-11
ATE431139T1 (de)	2009-05-15
JP2008220374A (ja)	2008-09-25
CN103611161A (zh)	2014-03-05
US20100286168A1 (en)	2010-11-11
WO2006076231A3 (en)	2007-01-18
HRP20090403T1 (hr)	2009-08-31
NZ578502A (en)	2011-01-28
WO2006076231A2 (en)	2006-07-20
CL2010000565A1 (es)	2010-10-15
HN2006000971A (es)	2011-12-27
EP1808168B1 (en)	2009-06-03
JP2008239623A (ja)	2008-10-09
ATE432693T1 (de)	2009-06-15
ES2327268T5 (es)	2013-03-21
NO20101746L (no)	2007-09-27
NO20073816L (no)	2007-09-27
AR052082A1 (es)	2007-02-28
PT1758565E (pt)	2009-08-19
JP4912349B2 (ja)	2012-04-11
PA8659301A1 (es)	2008-12-18
US20100298333A1 (en)	2010-11-25
EP1758565B1 (en)	2009-05-13
EP2322150A2 (en)	2011-05-18
KR20120139849A (ko)	2012-12-27
MX2007008376A (es)	2008-01-11
PL1758565T5 (pl)	2013-03-29
US20100286153A1 (en)	2010-11-11
TW200637534A (en)	2006-11-01
US8198232B2 (en)	2012-06-12
NI200700174A (es)	2008-05-09
JP4118323B1 (ja)	2008-07-16
US20070072803A1 (en)	2007-03-29
ES2327268T9 (es)	2013-11-12
AU2006205164A1 (en)	2006-07-20
PE20100398A1 (es)	2010-06-07
CN102218141A (zh)	2011-10-19
NO331089B1 (no)	2011-10-03
KR20130140226A (ko)	2013-12-23
JP2008195733A (ja)	2008-08-28
KR20100129328A (ko)	2010-12-08
NZ556219A (en)	2010-09-30
US20060154866A1 (en)	2006-07-13
EP1758565A2 (en)	2007-03-07
KR20070095400A (ko)	2007-09-28
NZ587368A (en)	2011-01-28
AU2009202900B2 (en)	2010-02-11
EP2116235A1 (en)	2009-11-11
JP2012017330A (ja)	2012-01-26
JP2008110964A (ja)	2008-05-15
JP4787804B2 (ja)	2011-10-05
EP1758565B2 (en)	2012-11-14
PE20061116A1 (es)	2006-10-12
DE602006007093D1 (de)	2009-07-16
US20100285495A1 (en)	2010-11-11
SI1808168T1 (sl)	2009-10-31
US20100286111A1 (en)	2010-11-11
KR20100072085A (ko)	2010-06-29
EA200701469A1 (ru)	2008-02-28
PL1808168T3 (pl)	2009-11-30
US20100137293A1 (en)	2010-06-03
JP2011184458A (ja)	2011-09-22
US7803753B2 (en)	2010-09-28
RS51127B (sr)	2010-10-31
AU2006205164B2 (en)	2011-09-08
EP2322151A2 (en)	2011-05-18
BRPI0606727A (pt)	2008-03-11
KR101016890B1 (ko)	2011-02-22
HRP20090446T1 (hr)	2009-09-30
US20100291589A1 (en)	2010-11-18
CA2654733A1 (en)	2006-07-20
EP1808168A1 (en)	2007-07-18
AU2009202898B2 (en)	2010-02-18
US8030270B2 (en)	2011-10-04
AU2009202898A1 (en)	2009-08-06
PT1808168E (pt)	2009-08-25
EP2322151A3 (en)	2012-01-18
CY1109260T1 (el)	2014-07-02
US8003597B2 (en)	2011-08-23
DK1758565T4 (da)	2013-02-04
JP2008526235A (ja)	2008-07-24
EP2322156A1 (en)	2011-05-18
US20070072804A1 (en)	2007-03-29
HK1100353A1 (en)	2007-09-21
CY1109321T1 (el)	2014-07-02
CR9220A (es)	2009-07-31
AU2009202900A1 (en)	2009-08-06
ES2327268T3 (es)	2009-10-27
US7803754B2 (en)	2010-09-28
NZ578504A (en)	2011-02-25
ES2327872T3 (es)	2009-11-04
DOP2006000008A (es)	2006-08-31
EP2322150A3 (en)	2011-11-16
US20100285494A1 (en)	2010-11-11
EP1997484A2 (en)	2008-12-03

Publication	Publication Date	Title
DK1758565T3 (da)	2009-09-07	Fremgangsm de til identifikation af GLP-1-sekretionsfremkaldende stoffer
FR2881809B1 (fr)	2007-04-13	Bloqueur de lacet rapide
EP1997271A4 (en)	2014-08-27	SINGLE-SIGN-ON BETWEEN SYSTEMS
FI20055581L (fi)	2007-04-29	Erotusmenetelmä
DK2061746T3 (da)	2013-11-25	Fremgangsmåde til fremstilling af diestere
DK2061803T3 (da)	2019-11-18	Fremgangsmåde til oprensning af fc-holdige proteiner
BRPI0813569A2 (pt)	2014-12-23	Método de inspeção.
DE602006020301D1 (de)	2011-04-07	Schnellverbinder
DK3417905T4 (en)	2023-11-20	Applikator til indføring af et implantat
DK2993233T3 (da)	2019-08-19	Forbedret promoter og en fremgangsmåde til fremstilling af l-lysin ved anvendelse af samme
BRPI0810416A2 (pt)	2014-10-14	Método de hidroformação
DK1856024T3 (da)	2008-11-24	Fremgangsmåde til fremstilling af substituerede biphenyler
EP2087842A4 (en)	2012-10-17	IMAGING DEVICE
EP2114870A4 (en)	2011-10-12	SYNTHETIC ION CHANNELS
ITTO20050184A1 (it)	2005-09-23	Connettore rapido
IT1392297B1 (it)	2012-02-24	Proiettore per palcoscenico e gruppo proiettore comprendente detto proiettore per palcoscenico
FI20065363A0 (fi)	2006-05-30	Erotusmenetelmä
DK1994138T3 (da)	2014-05-12	Fremgangsmåde til fremstilling af humant g-csf
ITMO20050254A1 (it)	2007-04-07	Gruppo abrasivo
BRPI0618419A2 (pt)	2016-09-06	retorno rápido
DK1834528T3 (da)	2014-07-14	Fremgangsmåde til fremstilling af gelé-agtige drikke
FI20055246L (fi)	2006-11-25	Verkkojen välinen palveluyhteistoiminta
DE602006000599D1 (de)	2008-04-17	Kochvorrichtung
DK1717311T3 (da)	2013-01-14	Fremgangsmåde til fremstilling af lactoperoxidase
DK1955066T3 (da)	2014-05-05	Membran-assay-fremgangsmåde